Amgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Head And Neck Cancer Read more about Amgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Head And Neck Cancer
Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Read more about Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease
Amgen Launches Program To Further Advance Basic Biology Research Read more about Amgen Launches Program To Further Advance Basic Biology Research
Amgen To Present At The Jefferies 2015 Global Healthcare Conference Read more about Amgen To Present At The Jefferies 2015 Global Healthcare Conference
Amgen To Advance Understanding Of The Treatment Of Blood Cancers At 20th Congress of European Hematology Association (EHA) Read more about Amgen To Advance Understanding Of The Treatment Of Blood Cancers At 20th Congress of European Hematology Association (EHA)
Amgen to Terminate Participation in Co-development and Commercialization of Brodalumab Read more about Amgen to Terminate Participation in Co-development and Commercialization of Brodalumab
Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma Read more about Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma
Amgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High Cholesterol Read more about Amgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High Cholesterol
Amgen Appoints Jonathan P. Graham Senior Vice President, General Counsel And Secretary Read more about Amgen Appoints Jonathan P. Graham Senior Vice President, General Counsel And Secretary
Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine Read more about Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine
